Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Rua Pedro de Toledo 669, Vila Clementino, Sao Paulo, Brazil.
Endocr Metab Immune Disord Drug Targets. 2020;20(3):321-327. doi: 10.2174/1871530319666190828145854.
Asthma is correlated with a higher risk of manifesting other diseases, including hypertension, diabetes, obesity, psychiatric and neurological diseases, and cancer. Therefore, revealing this interplay between asthma and these illnesses may provide novel insights into their pathogenesis.
It is highly debated that dysregulation of Ca2+ homeostasis is involved in the pathogenesis of these maladies. Not surprisingly, calcium (Ca2+) channel blockers (CCBs), classically used as antihypertensive medicines, have been demonstrating off-label effects such as alleviating asthma symptoms, in addition to antidiabetic, antiobesity, anticancer and antineurodegenerative effects. Our studies about Ca2+/cAMP signalling may shed some new light on this field.
Thus, considering that asthma and associated illnesses such as hypertension, diabetes, obesity, cancer and neurodegenerative diseases have become highly prevalent medical problems in the world, the comprehension of this interplay between asthma and other disorders could improve drug therapy.
哮喘与表现出其他疾病的风险增加相关，包括高血压、糖尿病、肥胖、精神和神经疾病以及癌症。因此，揭示哮喘与这些疾病之间的这种相互作用可能为它们的发病机制提供新的见解。
钙稳态失调参与这些疾病的发病机制，这一点备受争议。毫不奇怪，钙 (Ca2+) 通道阻滞剂 (CCB) 作为经典的降压药物，除了具有抗糖尿病、抗肥胖、抗癌和抗神经退行性作用外，还具有缓解哮喘症状等标签外效应。我们关于 Ca2+/cAMP 信号的研究可能为此领域带来一些新的启示。
因此，考虑到哮喘以及高血压、糖尿病、肥胖、癌症和神经退行性疾病等相关疾病已成为世界上高度流行的医学问题，理解哮喘与其他疾病之间的这种相互作用可以改善药物治疗。
